Community-based adverse food reactions and anaphylaxis in children with IgE-mediated food allergy at age 6 years: a population-based study

Allergic Diseases

Timing of Introduction, Sensitization and Allergy to Highly-Allergenic Foods at Age 3 Years in a General-Population Canadian Cohort

J Allergy Clin Immunol Pract.

Simons E, Balshaw R, Lefebvre DL, Dai D, Turvey SE, Moraes TJ, Mandhane PJ, Azad MB, Sears MR, Subbarao P, Becker AB

doi: 10.1016/j.jaip.2019.09.039.

Immunotherapy

Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis

Allergy.

Nurmatov U, Dhami S, Arasi S, Pajno GB, Fernandez-Rivas M, Muraro A, Roberts G, Akdis C, Alvaro-Lozano M, Beyer K, Bindslev-JensenC, Burks W, du Toit G, Ebisawa M, Eigenmann P, Knol E, Makela M, Nadeau KC, O'Mahony L, Papadopoulos N, Poulsen LK, Sackesen C, Sampson H, Santos AF, van Ree R, Timmermans F, Sheikh A

doi: 10.1111/all.13124.

Allergic Diseases

Frequency of food allergy in school-aged children in eight European countries - the EuroPrevall-iFAAM birth cohort

Allergy.

Grabenhenrich L, Trendelenburg V, Bellach J, Yürek S, Reich A, Fiandor A, Rivero D, Sigurdardottir ST, Clausen M, Papadopoulos NG, Xepapadaki P, Sprikkelman AB, Dontje B, Roberts G, Grimshaw K, Kowalski ML, Kurowski M, Dubakiene R, Rudzeviciene O, Fernández-Rivas M, Couch P, Versteeg SA, van Ree R, Mills E, Keil T, Beyer K

doi: 10.1111/all.14290.

Atopic Dermatitis

Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study

Br J Dermatol

Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Sun X, Chen Z, Akinlade B, Boklage S, Guillemin I, Kosloski MP, Kamal MA, O'Malley JT, Patel N, Graham NMH, Bansal A

doi: 10.1111/bjd.19460

Atopic Dermatitis

Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study

Br J Dermatol.

Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Sun X, Chen Z, Akinlade B, Boklage S, Guillemin I, Kosloski MP, Kamal MA, O'Malley JT, Patel N, Graham NMH, Bansal A

doi: 10.1111/bjd.19460.

Allergic Diseases

Prevalence of Food Sensitization and Food Allergy in Children across Europe

J Allergy Clin Immunol Pract.

Lyons SA, Clausen M, Knulst AC, Ballmer-Weber BK, Fernandez-Rivas M, Barreales L, Bieli C, Dubakiene R, Fernandez-Perez C, Jedrzejczak-Czechowicz M, Kowalski ML, Kralimarkova T, Kummeling I, Mustakov TB, Papadopoulos NG, Popov TA, Xepapadaki P, Welsing PMJ, Potts J, Mills ENC, van Ree R, Burney PGJ, Le TM

doi: 10.1016/j.jaip.2020.04.020.

Immunotherapy

Oral and Sublingual Immunotherapy for Treatment of IgE-Mediated Food Allergy

Clin Rev Allergy Immunol.

Scurlock AM

doi: 10.1007/

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

A Nationwide Study of Severe Cutaneous Adverse Reactions Based on the Multicenter Registry in Korea

J Allergy Clin Immunol Pract.

Kang DY, Yun J, Lee SY, Koh YI, Sim DW, Kim S, Nam YH, Park JW, Kim SH, Ye YM, Park HK, Kim MH, Jee YK, Jung JW, Yang MS, Kim SH, Lee JK, Kim CW, Hur GY, Kim MY, Park SJ, Kwon YE, Choi JH, Kim JH, Kim SH, La HO, Kang MG, Park CS, Lee SM, Jeong YY, Kim HK, Jin HJ, Jeong JW, Lee J, Lee YW, Lee SE, Kim MS, Kang HR, Korean Severe Cutaneous Adverse Reactions Consortium.

doi: 10.1016/j.jaip.2020.09.011.

Allergic DiseasesImmunotherapy

Oral desensitization in IgE-mediated food allergy: Effectiveness and safety

Pediatr Allergy Immunol.

Calvani M, Bianchi A, Imondi C, Romeo E

doi: 10.1111/pai.13171.

Related content

Timing of Introduction, Sensitization and Allergy to Highly-Allergenic Foods at Age 3 Years in a General-Population Canadian Cohort

Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis

Frequency of food allergy in school-aged children in eight European countries - the EuroPrevall-iFAAM birth cohort

Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study

Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study

Prevalence of Food Sensitization and Food Allergy in Children across Europe

Oral and Sublingual Immunotherapy for Treatment of IgE-Mediated Food Allergy

A Nationwide Study of Severe Cutaneous Adverse Reactions Based on the Multicenter Registry in Korea

Oral desensitization in IgE-mediated food allergy: Effectiveness and safety